Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FlutiForm 250 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | FlutiForm 250/10 ug |
| 2 | EXPERIMENTAL | FlutiForm 100/10 ug |
| 3 | ACTIVE_COMPARATOR | Oral Prednisone 10 mg |
| 4 | PLACEBO_COMPARATOR | Placebo inhaler and/or placebo tablets |
| Name | Type | Description |
|---|---|---|
| FlutiForm 250/10 ug | DRUG | SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 6 weeks. |
| FlutiForm 100/10 ug | DRUG | SKP FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 6 weeks. |
| Oral Prednisone 10mg | DRUG | 2 x 5 mg oral prednisone tablets, over encapsulated, once a day for one week. |
| Placebo | DRUG | 2 x 5 mg placebo tablets, over encapsulated, once a day for six weeks. SKP FlutiForm placebo HFA pMDI. Two actuations BID for six weeks. |
Inclusion Criteria: * Age 18-65 at the Screening Visit; * History of asthma for at least 6 months prior to Screening Visit * Well controlled asthma with rescue short acting beta agonist (albuterol) and or stable doses of other medications for at least 4 weeks prior to Screening Visit * Female subje...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
FlutiForm 250 is an investigational inhaled therapy being studied for the treatment of asthma. It is a small molecule product developed by Pacira BioSciences, Inc. and has been evaluated in a Phase 1 clinical trial in adult asthma patients. It is not approved for commercial use.
FlutiForm 250 is being developed by Pacira BioSciences, Inc., which trades on the Nasdaq under the ticker PCRX. The company sponsored the Phase 1 asthma study of the product.
FlutiForm 250 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The product remains investigational and has not been approved by the FDA for any indication.
FlutiForm 250 has been studied in one completed Phase 1 trial, NCT00657774. That randomized, double-blind, placebo-controlled study enrolled 160 adults with asthma in the United States and evaluated the effect of FlutiForm doses on cortisol produced by the adrenal glands.